CSF1R and breast carcinoma: The previous study hypothesized that the trans-(−)-isoform was the preferred active form in the trans racemic mixture [43], binding CSF1R at the juxtamembrane region (JM) in the same way that pexidartinib does, resulting in suppression of CSF1R and its downstream molecules on breast cancer cells [42].